How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits.

Martin, NK; Vickerman, P; Dore, GJ; Grebely, J; Miners, A; Cairns, J; Foster, GR; Hutchinson, SJ; Goldberg, DJ; Martin, TC; +3 more... Ramsay, M; STOP-HCV Consortium; Hickman, M; (2016) How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits. Journal of hepatology, 65 (1). pp. 17-25. ISSN 0168-8278 DOI: https://doi.org/10.1016/j.jhep.2016.02.007

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.jhep.2016.02.007

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar